A Study of LY3050258 in Healthy Participants
| Status: | Completed |
|---|---|
| Conditions: | Healthy Studies |
| Therapuetic Areas: | Other |
| Healthy: | No |
| Age Range: | 30 - 80 |
| Updated: | 8/29/2018 |
| Start Date: | August 2013 |
| End Date: | December 2013 |
A Single-Dose, Dose Escalation, Safety, Tolerability, and Pharmacokinetic Study of LY3050258
The main purpose of this study is to evaluate the safety and how well the body will handle a
single dose of increasing strength of study drug LY3050258. Each participant will receive
LY3050258 or placebo once, in each of 2 dosing periods. At least 7 days will pass between
doses. This study will last approximately 45 days for each participant. Screening is required
within 28 days before the start of the study.
single dose of increasing strength of study drug LY3050258. Each participant will receive
LY3050258 or placebo once, in each of 2 dosing periods. At least 7 days will pass between
doses. This study will last approximately 45 days for each participant. Screening is required
within 28 days before the start of the study.
Inclusion Criteria:
- Healthy males or healthy postmenopausal females, including Japanese participants
- Have a body mass index (BMI) of 18 to 35 kilograms per square meter (kg/m^2)
Exclusion Criteria:
- An abnormal sitting blood pressure as determined by the investigator
- Any abnormality in the 12-lead electrocardiogram (ECG) that, in the opinion of the
investigator, places the participant at an unacceptable risk for study participation
- Current use of statins within the last 3 months prior to dosing
- Current or previous use of anabolic steroids in the preceding 6 months prior to dosing
- Use of dehydroepiandrosterone, other potential over-the-counter (OTC) steroidal
supplements, or other nutritional products intended to have weight-reduction and/or
performance-enhancing effects within 21 days prior to dosing
We found this trial at
1
site
Click here to add this to my saved trials
